Novo Nordisk shares have hemorrhaged roughly 68% of their value across the past 24 months. For a pharmaceutical giant that previously dominated the obesity treatment landscape, this decline represents a dramatic reversal of fortune. Yet beneath the surface, several developments warrant closer examination.
During the American Diabetes Association’s 2026 Scientific Sessions, the Danish drugmaker unveiled multiple retrospective analyses drawn from its SELECT, STEP, ESSENCE, and OASIS clinical programs. These evaluations explored how semaglutide — the compound powering both Wegovy and Ozempic — influences health outcomes extending beyond simple weight reduction.
One retrospective examination revealed that participants receiving 2.4 mg semaglutide injections experienced a 52% reduction in obstructive sleep apnea incidence relative to those on placebo, reflected in a 0.48 hazard ratio. Among subjects free of OSA initially, the treatment arm documented 30 new diagnoses compared with 65 in the control cohort.
A separate evaluation centered on asthma outcomes. Individuals managing established cardiovascular disease, asthma, and obesity who received semaglutide recorded fewer asthma-associated adverse events — 27 instances versus 46 among placebo recipients, yielding a 0.58 hazard ratio. Additionally, high-sensitivity C-reactive protein, an inflammation indicator, decreased by 38.9%.
Regarding cardiovascular metrics, consolidated STEP trial data indicated semaglutide lowered systolic blood pressure by approximately 5.48 mmHg beyond placebo effects in participants with inadequately controlled hypertension. Diastolic readings fell by 2.73 mmHg.
Findings from the ESSENCE investigation demonstrated sustained enhancement in cardiometabolic risk parameters and hepatic biomarkers through week 72, independent of participants’ initial glycemic status.
The potentially more significant development involves amycretin. Novo Nordisk disclosed phase 2 findings indicating this investigational agent — a dual GLP-1 and amylin receptor agonist unified in one molecule — produced weight reductions reaching 14.6% alongside A1C decreases of 1.71 percentage points from a 7.8% starting point across 36 weeks. Placebo participants achieved merely 2.1% weight reduction.
Importantly, higher dosing levels showed no evident plateauing of weight loss effects. This dose-responsive pattern represents precisely what analysts and clinical researchers hope to observe before phase 3 initiation.
Unlike CagriSema, which pairs two distinct molecular entities, amycretin exists as a unified compound. This structural difference could translate to superior therapeutic performance and streamlined production processes. The company intends to pursue both injectable and oral delivery formulations.
The preceding two years have proven challenging. Eli Lilly’s Zepbound demonstrated superior weight reduction outcomes in comparative trials, while CagriSema underperformed the 25% average weight loss objective company leadership had anticipated. The compound also suffered defeat in direct comparison testing against Zepbound.
Financial performance has deteriorated. Novo Nordisk downwardly revised its revenue projections multiple times throughout 2025 and presently anticipates declining sales for the 2026 fiscal period.
The oral Wegovy tablet has emerged as a positive development, attracting patients previously hesitant about injectable medications. Experimental candidate UBT251, a triple gut hormone agonist, has delivered encouraging phase 2 outcomes in Chinese clinical trials.
The upcoming critical catalysts include amycretin phase 3 protocol specifications and any comparative effectiveness data against rival GLP-1 receptor agonists.
The post Novo Nordisk (NVO) Stock: Can Amycretin Revive the Struggling Weight-Loss Giant? appeared first on Blockonomi.
